Efficacy and Safety of Cangrelor on Top of AnticoagUlation in Patients with MyocaRdial Infarction Related Cardiogenic Shock/Cardiac Arrest ReceiVIng VAECMO Support - a Phase 2, Single Arm, Single Center Trial
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Cangrelor (Primary)
- Indications Coronary thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SURVIVE
- 03 Feb 2025 New trial record